Financial Performance - The company's operating revenue for Q3 2023 reached ¥66,249,915.76, representing a year-on-year increase of 25.70%[5] - Net profit attributable to shareholders for Q3 2023 was ¥18,921,491.22, a significant increase of 110.17% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥13,421,541.04, up 90.45% year-on-year[6] - Basic earnings per share for Q3 2023 were ¥0.36, an increase of 57.63% compared to the same period last year[6] - The total comprehensive income for Q3 2023 was ¥64,844,408.23, compared to ¥43,477,868.32 in Q3 2022, representing a significant increase[25] - Basic and diluted earnings per share for Q3 2023 were both ¥1.47, up from ¥1.09 in Q3 2022, indicating a growth of approximately 34.86%[25] - Operating revenue for the first three quarters of 2023 was CNY 213,814,563.87, up 30% from CNY 164,281,117.11 in the same period of 2022[23] - Net profit for the first three quarters of 2023 was CNY 64,844,408.23, representing a 49% increase compared to CNY 43,477,868.32 in the first three quarters of 2022[24] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥2,205,790,603.34, reflecting an increase of 322.78% compared to the end of the previous year[6] - The total equity attributable to shareholders at the end of Q3 2023 was ¥2,106,676,149.83, an increase of 418.40% compared to the previous year[6] - The company's total assets as of September 30, 2023, reached CNY 2,205,790,603.34, a significant increase from CNY 521,736,859.58 on December 31, 2022[19] - The total liabilities decreased to CNY 99,114,453.51 as of September 30, 2023, down from CNY 115,357,900.08 at the end of 2022[21] - The total equity increased to CNY 2,106,676,149.83 as of September 30, 2023, compared to CNY 406,378,959.50 at the end of 2022[21] Cash Flow - The cash flow from operating activities for Q3 2023 was ¥4,352,268.01, down 71.75% year-on-year, primarily due to increased R&D and sales expenses[12] - Cash inflow from operating activities for the first three quarters of 2023 was ¥224,314,725.42, an increase from ¥198,139,783.25 in the same period of 2022, reflecting a growth of about 13.19%[27] - Net cash flow from operating activities decreased to ¥18,264,575.62 in 2023 from ¥37,843,151.01 in 2022, showing a decline of approximately 51.74%[27] - Cash inflow from investment activities surged to ¥1,180,039,492.65 in 2023, compared to ¥135,956,802.93 in 2022, marking a substantial increase of about 767.67%[28] - Net cash flow from investment activities was negative at -¥1,334,959,639.88 in 2023, worsening from -¥219,595,832.34 in 2022[28] - Cash inflow from financing activities amounted to ¥1,655,153,231.93 in 2023, with no inflow recorded in the same period of 2022[28] - The net increase in cash and cash equivalents for the first three quarters of 2023 was ¥307,113,371.12, contrasting with a decrease of -¥190,047,617.03 in 2022[28] - The ending balance of cash and cash equivalents as of September 30, 2023, was ¥639,999,065.47, compared to ¥114,187,705.33 at the end of Q3 2022[28] Research and Development - Research and development expenses totaled ¥11,139,651.93 in Q3 2023, marking a 52.78% increase year-on-year, and accounted for 16.81% of operating revenue[6] - Research and development expenses for the first three quarters of 2023 totaled CNY 27,418,108.68, an increase of 42% from CNY 19,311,489.82 in the same period of 2022[23] - The company is focused on expanding its product offerings and improving its competitive edge through technological innovation and collaboration with authoritative hospitals and industry experts[18] - The company plans to enhance its product production efficiency and consistency through the new industrial base, which will support core product capacity expansion[18] - The new R&D laboratory and office space, along with advanced testing and experimental equipment, will significantly enhance the company's R&D capabilities[18] - The construction of the minimally invasive surgical medical device R&D and industrialization base is progressing smoothly, with the civil engineering phase nearly completed and expected to be operational by the end of 2024[18] Market Strategy - The company plans to continue expanding its market presence and enhancing its product offerings, particularly in surgical power devices and consumables[11] - The company reported a year-to-date revenue increase of 30.15%, driven by enhanced marketing efforts and a broader distribution network[11] - The company aims to establish branch offices in key provinces to promote regional business, sales, and after-sales services, thereby increasing brand influence and market share[18] Shareholder Information - The company reported a significant shareholder concentration, with the top 10 shareholders holding a total of 36.06% of the shares[15] - The largest shareholder, Chongqing Xishan Investment Co., Ltd., holds 19,114,290 shares, representing 36.06% of the total shares[15] - The company has a total of 1,638,241 shares held by individual shareholder Guo Yijun, accounting for 3.09% of the total shares[15] Tax and Financial Income - The company received ¥5,079,578.20 in tax refunds during the first three quarters of 2023, significantly higher than ¥1,162,948.64 in the same period of 2022, indicating an increase of approximately 337.56%[27] - The company reported a financial income of CNY 4,508,689.29 for the first three quarters of 2023, compared to CNY 2,279,459.52 in the same period of 2022[23]

（一）审议通过《关于公司 2023 年第三季度报告的议案》 证券代码：688576 证券简称：西山科技 公告编号：2023-020 重庆西山科技股份有限公司 第三届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任 一、 监事会会议召开情况 重庆西山科技股份有限公司（以下简称"公司"）第三届监事会第十二次会 议于 2023 年 10 月 27 日上午 10:00 以现场会议方式在公司一会议室召开。应出 席会议监事 3 名，实际出席会议监事 3 名，会议由监事会主席常婧召集和主持。 会议通知于 2023 年 10 月 20 日通过书面方式和电话等方式发出。 本次会议的召开符合《公司法》和《公司章程》的有关规定。会议经过审核、 表决，通过以下决议： 二、 监事会会议审议情况 监事会认为：公司 2023 年第三季度报告客观真实地反映了报告期内公司的 财务状况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。因此， 监事会一致同意本议案。 表决情况：同意 3 票，反对 0 票，弃权 0 票，回避 0 票。 ...

证券代码：688576 证券简称：西山科技 公告编号：2023-021 重庆西山科技股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 说明会类型 重庆西山科技股份有限公司（以下简称"公司"）于 2023 年 10 月 28 日在上 海证券交易所网站（www.sse.com.cn）披露《2023 年第三季度报告》。为便于广 大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司计划于 2023 年 11 月 03 日（星期五）15:00-16:00 在"价值在线"（www.ir-online.cn）举 办重庆西山科技股份有限公司 2023 年第三季度业绩说明会，与投资者进行沟通 和交流，广泛听取投资者的意见和建议。 会议召开时间：2023 年 11 月 03 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2023 ...

2023 年 10 月 17 日，公司接到实际控制人、董事长兼总经理郭毅军先生拟 以自有资金或自筹资金通过上海证券交易所交易系统允许的方式（包括但不限于 集中竞价、连续竞价和大宗交易等）增持公司股份的告知函。现将有关情形公告 如下： 一、 增持主体的基本情况 证券代码：688576 证券简称：西山科技 公告编号：2023-019 重庆西山科技股份有限公司 关于实际控制人、董事长兼总经理增持公司股份计 划的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一）增持主体的姓名：公司实际控制人、董事长兼总经理郭毅军先生。 重庆西山科技股份有限公司（以下简称"公司"）实际控制人、董事长 兼总经理郭毅军先生基于对公司未来发展的信心和长期投资价值认可， 拟使用其自有资金或自筹资金,自 2023 年 10 月 30 日起 6 个月内，通过 上海证券交易所系统允许的方式（包括但不限于集中竞价、连续竞价和 大宗交易）增持公司股份，本次计划增持股份数量不低于 20,000 股。 本次增持计划可能存在因证券市场情况发生变化 ...

重庆西山科技股份有限公司 投资者关系活动记录表 证券简称：西山科技 证券代码：688576 编号：2023-004 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 电话会议 □券商策略会 □其他 参与单位名称 泰康资产、泰康基金、国盛证券、景顺长城基金 时间 2023年10月12日 地点 公司会议室 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching CNY 500 million, representing a 25% year-over-year growth[14]. - The net profit for the first half of 2023 was CNY 100 million, up 30% compared to the same period last year[14]. - The company achieved operating revenue of CNY 147.56 million, a year-on-year increase of 32.25%[21]. - Net profit attributable to shareholders reached CNY 45.92 million, up 33.21% compared to the same period last year[21]. - Basic earnings per share increased to CNY 1.16, reflecting a growth of 33.33% year-on-year[20]. - The weighted average return on equity rose to 10.66%, an increase of 0.65 percentage points from the previous year[20]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[14]. Research and Development - Investment in R&D has increased by 40%, focusing on innovative medical devices and surgical technologies[14]. - Research and development expenditure accounted for 11.03% of operating revenue, up 0.26 percentage points year-on-year[20]. - The total R&D expenditure for the current period is ¥16,278,456.75, representing a 35.43% increase compared to ¥12,020,096.91 in the same period last year[45]. - The number of R&D personnel increased to 112, representing 19.05% of the total workforce, up from 15.37% in the previous year[54]. - The total compensation for R&D personnel reached 778.05 million RMB, compared to 592.09 million RMB in the prior year, indicating a year-over-year increase of about 31.5%[54]. - The company has established key technology sectors including medical micro-motors and transmission technology, which are crucial for product design and manufacturing[56]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[14]. - The company has outlined its future outlook, projecting a revenue growth of 15% for the second half of 2023, driven by new product launches and market expansion[14]. - The company has strengthened sales expansion and improved product recognition in domestic and international hospitals, leading to increased market demand[21]. - The company is focusing on expanding its market presence in minimally invasive surgical tools, leveraging its existing product advantages and customer recognition[66]. Product Development and Innovation - The company has introduced two new products in the energy surgical equipment line, aiming to capture a larger segment of the surgical market[14]. - The company has developed a breast lesion rotary biopsy system, the first of its kind among domestic brands to achieve industrialization and obtain medical device registration[33]. - The company has successfully developed and obtained medical device registration certificates for new products including plasma surgical equipment and 4K endoscopic systems, demonstrating its strong product innovation capabilities[58]. - The company has registered and launched products utilizing the directional grinding drill technology, expanding its market presence in the minimally invasive surgery sector[36]. Risks and Challenges - The company has identified potential risks, including regulatory changes and market competition, which could impact future performance[14]. - The company faces risks related to market competition, particularly from established multinational companies like Medtronic and Stryker[70]. - The growth of disposable consumables is critical for the company's future, but it may be hindered by clinical recognition and reimbursement policies[71]. - The company is at risk of project halts or failures in new product development due to high investment and uncertainty in the medical device industry[71]. Environmental and Governance - The company has established mechanisms for environmental protection and adheres to pollution discharge standards, with all pollutants treated appropriately[90]. - The company has a long-term commitment to environmental responsibility and has not faced any administrative penalties related to environmental issues[90]. - The company’s governance and decision-making processes for shareholder meetings were conducted in accordance with legal regulations and company bylaws[84]. - The company has not faced any violations or penalties related to its directors, supervisors, or senior management during the reporting period, indicating good governance[124]. Shareholder Commitments and IPO - The company went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 6, 2023, to further enhance its competitive edge[62]. - The controlling shareholder, Xishan Investment, committed to not transferring or entrusting the management of shares for 36 months from the date of the company's stock listing[97]. - The actual controller and senior management, Guo Yijun, also committed to a 36-month lock-up period for shares held prior to the IPO[98]. - The company will ensure that any gains from violations of the lock-up commitments will be returned to the company within five working days[99]. Financial Position - The company's total assets grew by 318.19% to CNY 2.18 billion compared to the end of the previous year[22]. - The company's net assets attributable to shareholders increased by 413.41% to CNY 2.09 billion compared to the end of the previous year[22]. - The company's cash and cash equivalents surged to CNY 1,866,536,716.80 as of June 30, 2023, from CNY 332,885,694.35 at the end of 2022, marking an increase of about 461.5%[154]. - The company's equity increased significantly to CNY 2,086,406,443.11 as of June 30, 2023, compared to CNY 406,378,959.50 at the end of 2022, representing a growth of approximately 413.5%[155].

证券代码：688576 证券简称：西山科技 公告编号：2023-017 重庆西山科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海 证券交易所科创板股票上市规则》等有关法律、法规及相关文件的规定，重庆西 山科技股份有限公司（以下简称"公司"或"本公司"）就 2023 年半年度募集 资金存放与实际使用情况专项报告说明如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意重庆西山科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2023]804 号），公司首次向社会公开发行人 民币普通股 1,325.0367 万股，每股面值 1.00 元，每股发行价格 135.80 元。本 次公开发行募集资金总额为人民币 179,939.98 万元，实际募集资金净额为 ...

证券代码：688576 证券简称：西山科技 公告编号：2023-016 重庆西山科技股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任 一、 监事会会议召开情况 重庆西山科技股份有限公司（以下简称"公司"）第三届监事会第十一次会 议于 2023 年 8 月 29 日上午 10:00 以现场会议方式在公司一会议室召开。应出席 会议监事 3 名，实际出席会议监事 3 名，会议由监事会主席常婧召集和主持。会 议通知于 2023 年 8 月 18 日通过书面方式和电话等方式发出。 本次会议的召开符合《公司法》和《公司章程》的有关规定。会议经过审核、 表决，通过以下决议： 二、 监事会会议审议情况 （一）审议通过《关于公司 2023 年半年度报告及其摘要议案》 监事会认为：公司 2023 年半年度报告客观真实地反映了报告期内的经营情 况，体现了公司的财务状况和经营成果。因此，监事会一致同意本议案。 表决情况：同意 3 票，反对 0 票，弃权 0 票，回避 0 票。 （二）审议通过《关于增加使用暂 ...

我们作为公司的独立董事认为:2023年上半年,公司已按照相关规定对募 集资金进行了专户存储和使用,公司募集资金的存放和使用符合中国证监会、上 海证券交易所关于上市公司募集资金存放和使用的相关规定,不存在募集资金存 放和使用违规的情形。公司董事会编制的《2023 年半年度募集资金存放与实际 使用情况的专项报告》内容真实、准确、完整,不存在虚假记载、误导性陈述和 重大遗漏。 重庆西山科技股份有限公司独立董事 关于第三届董事会第十九次会议相关事项的独立意见 重庆西山科技股份有限公司(以下简称"公司")第三届董事会第十九次会议 审议《关于增加使用暂时闲置自有资金进行现金管理的议案》等议案,参照《上 海证券交易所科创板股票上市规则》《上市公司独立董事规则》等有关法律法规 及其他规范性文件的规定,本着实事求是、认真负责的态度,基于独立判断的立 场,本公司独立董事对公司第三届董事会第十九次会议审议的相关事项发表以下 独立意见: 一、关于增加使用暂时闲置自有资金进行现金管理的议案 我们作为公司的独立董事认为:提高公司资金使用效率,在保证公司主营业 务正常和资金安全的情况下,使用自有资金进行现金管理,有利于提高公司资金 的使用 ...

东方证券承销保荐有限公司 关于重庆西山科技股份有限公司 2023 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司持续督导工作指引》等有关法律、法规的规定， 东方证券承销保荐有限公司（以下简称"保荐机构"）作为重庆西山科技股份有 限公司（以下简称"西山科技"、"公司"）持续督导工作的保荐机构，负责西山 科技上市后的持续督导工作，并出具本持续督导跟踪报告。 | 序 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 号 | | | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体 的持续督导工作制定相应的工作计划 | 保荐机构已建立健全并有效执行了 | | | | 持续督导制度，并制定了相应的工作 | | | | 计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前， | 保荐机构已与西山科技签订承销与 | | | 与上市公司或相关当事人签署持续督导协议，明确双 | 保荐协议，该协议明确了双方在持续 | | | 方在持续督导期间的权利义务，并报上海证券交易所 | 督导期间的权利和义务， ...